HYDERABAD: In a dimly lit court in Gondia, Maharashtra, the air hummed with tension. Six athletes crouched low, their ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that safety and efficacy ...

A color vision test shows good correlation with cone and cone-rod dystrophy biomarkers and may offer a cost-effective replacement for ERG.

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Although any dog can develop health conditions, these breeds are the least likely to have ones that will break the bank.

Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...

Stargardt macular dystrophy (Stargardt disease ... loss was 1.6-fold greater than the area of RPE atrophy, which suggests that photoreceptor degeneration may precede RPE loss in STGD1.76 Moreover, ...

Engineering students like An Le (left) and Bo Wen (center) work with Professor Truong Nguyen (right) to develop AI tools that ...

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...

Lycopene — a natural plant extract that gives color to red and pink fruits and vegetables such as tomatoes, watermelons and papayas — may ease depression symptoms by enhancing brain cell ...

The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...